COMP <GO>
HAE vs JNJ // RSI-14 & 200D SMA MOMENTUM
Haemonetics Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HAE 3
— JNJ 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: HAE
LAST: $119.65 (-0.12%) • MKT CAP: $5.45B
rsi-technicals
63.3
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.00% | 67.90% | -8.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 25.50% | -17.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | 18.5x | +14.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | 2.97% | +1.81 | HAE | /fcf-yield <GO> |
| Operating Margin | 11.70% | 34.70% | -23.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 6.00% | -8.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.89 | 5.59 | -1.70 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | HAE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 63.3 | 60.4 | +2.92 | HAE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 23.0x | +117.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.45B | $662.49B | -$657.04B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | JNJ REV | HAE GROSS % | JNJ GROSS % | HAE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $94.19B | 59.0% | 67.9% | $260.4M | $19.70B |
| FY 2024 | $1.36B | $88.82B | 55.0% | 69.1% | $142.4M | $19.84B |
| FY 2023 | $1.31B | $85.16B | 44.0% | 44.0% | $122.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
JNJ // BETA 1.08